Background
Chronic inflammation plays a role in cognitive function in people with HIV (PWH). Soluble Urokinase Plasminogen Activator (suPAR) is a biomarker of chronic inflammation previously associated with cognitive impairment in a small study of men with HIV. Our study aimed to examine whether elevated suPAR levels are associated with domain-specific cognitive function in virally suppressed women with HIV (VS-WWH), potentially providing a pre-clinical indicator for cognitive complications.
Methods
suPAR levels were assessed in duplicate via ELISA (ViroGates; Denmark) from stored (-80C) plasma in a sample of 188 VS-WWH (all participants had VL <200 copies/mL, 50% with impairment in ≥2 cognitive domains) participating in the Chicago Cook County site of the MACS-WIHS Combined Cohort study. Blood samples were collected between November 2004 and September 2017 at either the same visit as the cognitive assessment for 179 (95%) participants or from the visit immediately prior (within 90 days of assessment) from the remainder. Participants completed biennial cognitive testing. Cognitive domains included attention, executive function, processing speed, verbal memory, verbal learning, verbal fluency, and motor function. Domain-specific cognitive impairment was defined as demographically adjusted T-scores ≤40. Multivariable linear regression models assessed associations between log-transformed suPAR and cognitive domain T-scores adjusting for age.
Results
VS-WWH had a mean age of 52, a mean CD4 of 693, 72% were Black, and 67% had completed high school education. The mean suPAR level was 3.23 ng/mL (variation coefficient 56.8%). Higher log suPAR levels were associated with poorer processing speed (β=-0.18, 95%CI -0.31, -0.04, P=0.01), verbal learning (β=-0.15, 95%CI -0.29, -0.02, P=0.029), verbal fluency (β=-0.14, 95%CI -0.27, -0.01, P=0.038), and motor function (β=-0.13, 95%CI -0.26, -0.00, P=0.045)(see Table). There were no associations with other cognitive domains.
Conclusions
These findings suggest that suPAR offers potential as an indirect biomarker for systemic chronic inflammation, verbal abilities, and psychomotor speed in this population. Although the effect sizes were small, further exploration of this molecule is warranted as it may be helpful as part of a larger pre-clinical predictive model of cognitive changes in this population. Elucidating the mechanisms of suPAR production in this context will contribute to our overall understanding of its applicability.
Table or Figure
![]()